Drug Profile
Research programme: bispecific antibodies - Bioverativ
Alternative Names: Factor VIIIa mimetic bispecific antibody - Bioverativ; FVIIIa mimetic bispecific antibody - Bioverativ; Non-factor bi-specific antibody - BioverativLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Bioverativ
- Class Antihaemorrhagics; Bispecific antibodies
- Mechanism of Action Factor X stimulants; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemophilia A